SCHEMBL2117442

SCHEMBL2117442

CC(=O)Nc1ccn(Cc2c(F)cccc2F)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STIM1 Q13586 2/20 0.60
ORAI1 Q96D31 2/20 0.60
EGFR P00533 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 3/20 0.47
TSHR P16473 2/20 0.47
HTT P42858 2/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ORAI3 Q9BRQ5 1/20 0.47
HPGD P15428 1/20 0.46
GAA P10253 1/20 0.46
CACNA1I Q9P0X4 4/20 0.46
CACNA1G O43497 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114123 0.91 EGFR (0.69) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL15164066 0.88 ALDH1A1 (0.47) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL3440077 0.88 STIM1 (0.50) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL3439983 0.85 STIM1 (0.49) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL2113322 0.85 MAPT (0.58) STIM1ORAI1SMN1; SMN2NPC1RAB9A
SCHEMBL3440079 0.84 EGFR (0.47) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL3439992 0.82 EGFR (0.51) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL15165805 0.82 STIM1 (0.45) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL15165823 0.80 NPC1 (0.45) STIM1ORAI1EGFRSMN1; SMN2NPC1
SCHEMBL17961157 0.80 CA5A (0.58) STIM1ORAI1EGFRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524750-B2 (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds GLAXO GROUP LIMITED (GB) 2013-09-03 US disclosed
US-8524750-B2 (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds GLAXO GROUP LIMITED (GB) 2013-09-03 US disclosed
EP-2419426-B1 (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS GLAXO GROUP LTD (GB) 2013-08-14 EP disclosed
US-20120095064-A1 (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-04-19 US disclosed
US-20120095064-A1 (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-04-19 US disclosed
WO-2010118852-A1 ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095064-A1 (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS H1-3, CHRM2, TBL3 STIM1 4553/4885ORAI1 4752/4885EGFR 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.